Prostate Cancer Clinical Trial Using Ciprofloxacin, Prednisone, CABAZITAXEL (XRP6258) and G-CSF (Granulocyte colony-stimulating factor)

- The folks at Sanofi are studying the effects of CABAZITAXEL (XRP6258); Prednisone; Ciprofloxacin; G-CSF (Granulocyte colony-stimulating factor) on Prostate Cancer in males ages 18 years and older. This clinical trial is slated to start July 2012 and is expected to end circa July 2015.

For site information, send an email with site number to
Overall Study Contact Info
StatusName Contact Phone
RecruitingFor site information, send an email with site number toContact-Us@sanofi.com

This study is officially titled, "A Phase IV, Multicenter, National, Non-comparative, Open-label Study of Cabazitaxel, Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Second-line Treatment of Patients With Metastatic Castration-resistant Prostate Cancer and After Failure of Docetaxel-based Chemotherapy. Descriptive Assessment of the Circulating Tumor Cells in This Context.."

Locations

Investigational Site Number 002

Sao Paulo, Brazil - Active, not recruiting

Investigational Site Number 001

Santo Andre, Brazil - Active, not recruiting

Investigational Site Number 005

Porto Alegre, Brazil - Active, not recruiting

Investigational Site Number 006

Lajeado, Brazil - Recruiting

Investigational Site Number 004

Curitiba, Brazil - Recruiting

Investigational Site Number 007

Centro, Brazil - Active, not recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.